Article
Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Gastroenterology - 1 Feb 2005
Debiec-Rychter Maria, Cools Jan, Dumez Herlinde, Sciot Raf, Stul Michel, Mentens Nicole, Vranckx Hilde, Wasag Bartosz, Prenen Hans, Roesel Johannes, Hagemeijer Anne, Van Oosterom Allan, Marynen Peter
Abstract excerpt
BACKGROUND AND AIMS: Resistance is a major challenge in the treatment of patients with gastrointestinal stromal tumors (GISTs). We investigated the mechanisms of resistance in patients with progressive GISTs with primary KIT mutations and the efficacy of the kinase inhibitor PKC412 for the inhibition of imatinib-resistant mutants. METHODS: We performed a cytogenetic analysis and screened for mutations of the KIT...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.